This list is an analysis based on recent market events. It's not an investment recommendation.
About
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
The current price of ZYME.TO is C$26.24 CAD — it has increased by +0% in the past 24 hours. Watch Zymeworks stock price performance more closely on the chart.
What is Zymeworks stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Toronto Exchange exchange Zymeworks stocks are traded under the ticker ZYME.TO.
What is Zymeworks market cap?▼
Today Zymeworks has the market capitalization of 1.92B
How many employees does Zymeworks have?▼
As of November 2, 2026, the company has 455 employees.